• Explore /
  • Poster
  • / Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).

Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).

Abstract Video & Slides Poster

Authors

Fred Saad

Fred Saad

University of Montréal Health Center, Montréal, QC, Canada

Fred Saad , Daniel J. George , Michael Cookson , Daniel Saltzstein , Ronald F. Tutrone , Marc B. Garnick , Bruce Brown , Sophia Lu , Mark Fallick , Sarah Hanson , E. David Crawford , Neal D. Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Hormone-Sensitive

Clinical Trial Registration Number

NCT03085095

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5073)

DOI

10.1200/JCO.2022.40.16_suppl.5073

Abstract #

5073

Poster Bd #

256

Abstract Disclosures

Similar Posters

First Author: Neal D. Shore

First Author: Daniel J. George

First Author: Jose De La Cerda

First Author: Patrick Campbell